ADENO-ASSOCIATED VIRUS VECTOR DELIVERY FOR MUSCULAR DYSTROPHIES

The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune sy...

Full description

Saved in:
Bibliographic Details
Main Authors POTTER Rachael, RODINO-KLAPAC Louise, GRIFFIN Danielle, PETERSON Ellyn, MENDELL Jerry R
Format Patent
LanguageEnglish
Spanish
Published 03.04.2023
Subjects
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune system. La descripción proporciona un método para tratar la distrofia muscular, en un sujeto que lo necesita, que comprende la administración de un vector de terapia génica, como un vector de virus adenoasociado (AAV), que expresa un gen de microdistrofina humana miniaturizada en combinación con una etapa de supresión del sistema inmunitario del sujeto.
Bibliography:Application Number: MX20220016332